<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="H1 { font-size: 150px; font-weight: 900; }  Coagultaion Testing  æ—å”éœ† 2023.05.31
 Overview of Hemostasis primary hemostasis åˆç´šæ­¢è¡€ secondary hemostasis äºŒç´šæ­¢è¡€  primary hemostasis åˆç´šæ­¢è¡€  è¡€å°æ¿çš„æ­£å¸¸åŠŸèƒ½ : ğŸ‘®ç›£æ¸¬è¡€ç®¡å…§çš®çš„å®Œæ•´æ€§ä¸¦åœ¨è¡€ç®¡æå‚·éƒ¨ä½å½¢æˆæ “å¡ä»¥é˜»æ­¢å’Œé˜²æ­¢è¡€æ¶²æ»²æ¼åˆ°è¡€ç®¡å¤– æ²’æœ‰è¡€ç®¡æå‚· : å‰åˆ—ç’°ç´ ï¼ˆprostaglandinï¼‰å’Œå…§çš®ç´°èƒåˆ†æ³Œçš„ä¸€æ°§åŒ–æ°®çš„æŠ‘åˆ¶ğŸ” è¡€ç®¡æå‚·å’Œå…§çš®æå‚·  äº¤æ„Ÿç¥ç¶“ç³»çµ±è¢«å•Ÿå‹•ä¸¦å¼•èµ·è¡€ç®¡æ”¶ç¸® collagen, fibronectin, and laminin : exposed to circulating blood ğŸ‘·è¡€å°æ¿é™„åœ¨æš´éœ²çš„å…§çš®ä¸‹åŸºè³ªè›‹ç™½ä¸Šï¼Œé–‹å§‹æ­¢è¡€æ “å½¢æˆéç¨‹     secretion of storage granule content  è¡€å°æ¿é¡†ç²’ : å«æœ‰æ•¸åƒç¨®è›‹ç™½è³ªï¼Œå•Ÿå‹•å¾Œé‡‹æ”¾ 3 major secretory granules  alpha-granules  å‡è¡€å› å­ï¼ˆIã€IIã€V å’Œ XIï¼‰ã€ fibrinolysis system components coagulation inhibitors complement components (C1 inhibitor, C3, and C4)   delta-granules  ADP   lysosomes     during platelet activation è¡€å°æ¿æ´»åŒ–  ï¼ˆADPã€thromboxane A2ï¼‰å•Ÿå‹•ä¿¡è™Ÿé€šè·¯ï¼Œå°‡ GPIIb/IIIa è½‰åŒ–ç‚º divalent fibrinogen fibrinogen ğŸ‘‰ èšé›†/å‡èš  platelet aggregation è¡€å°æ¿èšé›†  GPIIb/IIIa  å‹Ÿé›†é¡å¤–çš„è¡€å°æ¿   transmembrane ADP receptors P2Y1 and P2Y12  è¡€å°æ¿å½¢æ…‹å­¸è®ŠåŒ– è¡€å°æ¿èšé›†     secondary hemostasis äºŒç´šæ­¢è¡€  æ²’æµè¡€æ™‚ï¼š  inactive precursor enzymes (zymogens) åœ¨è¡€æ¼¿ä¸­å¾ªç’°   æµè¡€æ™‚ï¼š  å°è‡´fibrin polymerizationå’Œè¡€å°æ¿æ´»åŒ–ï¼Œ å½¢æˆclot   2 å€‹é€”å¾‘ :  extrinsic intrinsic       Coagulation Factor - I  I - fibrinogen II - prothrombin   III - tissue thromboplastin (tissue factor)   IV - ionized calcium ( Ca++ ) V - labile factor or proaccelerin   PL : platelet membrane phospholipid   VII - stable factor or proconvertin   Coagulation Factor - II VIII - antihemophilic factor IX - plasma thromboplastin component, Christmas factor X - Stuart-Prower factor XI - plasma thromboplastin antecedent XII - Hageman factor   XIII - fibrin-stabilizing factor   Extrinsic pathway  è¡€ç®¡æå‚·æˆ–å–®æ ¸ç´°èƒå•Ÿå‹•å°è‡´ VIIï¼ˆVIIaï¼‰å•Ÿå‹• å•Ÿå‹• IX (intrinsicï¼‰å’Œ Xï¼ˆcommonï¼‰  Intrinsic pathway  ç”± XII è½‰åŒ–ç‚º XIIa é–‹å§‹ XI å’Œ IX é€æ­¥è½‰åŒ–ç‚ºå…¶æ´»æ€§å½¢å¼ VIIIa ï¼ˆç”±thrombinå•Ÿå‹•ï¼‰  åœ¨æ´»åŒ–çš„è¡€å°æ¿è¡¨é¢ä½œç‚º IXa çš„Cofactor ä¿ƒé€² X to Xa     ç„¶å¾Œå…©æ¢è·¯å¾‘åŒ¯èšåˆ°Common Pathwyaå…±åŒè·¯å¾‘  Xå•Ÿå‹•ç‚ºXa Xa å°‡prothrombinè½‰åŒ–ç‚ºthrombinï¼Œcofactor Va å¯åŠ é€Ÿåæ‡‰ thrombinå°‡fibrinogenè½‰åŒ–ç‚ºfibrin fibrin clot å½¢æˆ   tertiary hemostasis or clot stabilization ä¸‰ç´šæ­¢è¡€æˆ–å‡å¡Šç©©å®š  thrombinçš„å°‡ XIII å•Ÿå‹•ç‚º XIIIa XIIIa cross-links stabilizing fibrin   Fibrinolysis çº–ç¶­è›‹ç™½æº¶è§£ï¼ˆå‡å¡Šæº¶è§£ï¼‰  tissue-type plasminogen (tPA) æˆ– uPA :  plasminogen to plasmin   plasminåˆ‡å‰²fibriné‡‹æ”¾fibrin degradation products(FDP) and D-dimer fibrinolysisé€Ÿç‡å–æ±ºæ–¼ tPA æ¿ƒåº¦ï¼Œè©²æ¿ƒåº¦ç”±ä»¥ä¸‹å› ç´ æ§åˆ¶:  å…§çš®åˆ†æ³Œ tPA çš„é€Ÿç‡ è‚è‡Ÿæ¸…é™¤ tPA çš„é€Ÿç‡ tPA inhibitorã€PAI-1çš„æ¿ƒåº¦   ç ´å£ tPA çš„åˆ†æ³Œã€æŠ‘åˆ¶å’Œæ¸…é™¤ä¹‹é–“çš„å¹³è¡¡å¯å°è‡´ :  å‡ºè¡€ï¼ˆfibrinolysisäº¢é€²ï¼‰ è¡€æ “å½¢æˆï¼ˆfibrinolysisæ¸›é€€ï¼‰     Errors in Sample Collection   åŸºæœ¬å‡è¡€äº”é …  ğŸ“PT ğŸ“ aPTTğŸ“ TTğŸ“ FIBğŸ“ DD   Prothrombin Time (PT) and INR Activated Partial Thromboplastin Time (aPTT) Thrombin Time (TT) Clauss Fibrinogen Assay D-dimer Test   Prothrombin Time (PT) and INR   VIIï¼ˆå¤–æºæ€§é€”å¾‘ï¼‰ã€å› å­ IIã€V å’Œ Xï¼Œä»¥åŠfibrinogenï¼ˆå…±åŒé€”å¾‘ï¼‰ PT çš„åƒè€ƒç¯„åœå› è©¦åŠ‘å’Œå„€å™¨è€Œç•°ï¼›é€šå¸¸åœ¨ 10 ç§’åˆ° 13 ç§’ä¹‹é–“ INR = (patient&rsquo;s PT/ Control PT)ISI  causes of PT prolongation  underlying conditions anticoagulants acute dilutional coagulopathy  Shortened PT may suggest a hypercoagulable state, but it is not used to guide patient care in practice."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle="><title>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.84393096b3899db7fcf941e10b02fd94.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.021556b96a3c2bac2659a9f1cb00f8e2.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Aug 28, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/coagulation_test.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>ğŸ“’ç›®éŒ„</summary><nav id=TableOfContents><ol><li><ol><li><a href=#æ—å”éœ†>æ—å”éœ†</a></li></ol></li></ol><ol><li><ol><li><a href=#primary-hemostasis--åˆç´šæ­¢è¡€>primary hemostasis åˆç´šæ­¢è¡€</a></li><li><a href=#secondary-hemostasis-äºŒç´šæ­¢è¡€>secondary hemostasis äºŒç´šæ­¢è¡€</a></li></ol></li><li><a href=#primary-hemostasis--åˆç´šæ­¢è¡€-1>primary hemostasis åˆç´šæ­¢è¡€</a><ol><li><a href=#secretion-of-storage-granule-content>secretion of storage granule content</a></li><li><a href=#during-platelet-activation-è¡€å°æ¿æ´»åŒ–>during platelet activation è¡€å°æ¿æ´»åŒ–</a></li><li><a href=#platelet-aggregation--è¡€å°æ¿èšé›†>platelet aggregation è¡€å°æ¿èšé›†</a></li></ol></li><li><a href=#secondary-hemostasis-äºŒç´šæ­¢è¡€-1>secondary hemostasis äºŒç´šæ­¢è¡€</a></li><li><a href=#coagulation-factor---i>Coagulation Factor - I</a></li><li><a href=#coagulation-factor---ii>Coagulation Factor - II</a></li><li><a href=#extrinsic-pathway>Extrinsic pathway</a></li><li><a href=#intrinsic-pathway>Intrinsic pathway</a></li><li><a href=#ç„¶å¾Œå…©æ¢è·¯å¾‘åŒ¯èšåˆ°common-pathwyaå…±åŒè·¯å¾‘>ç„¶å¾Œå…©æ¢è·¯å¾‘åŒ¯èšåˆ°Common Pathwyaå…±åŒè·¯å¾‘</a></li><li><a href=#tertiary-hemostasis-or-clot-stabilization-ä¸‰ç´šæ­¢è¡€æˆ–å‡å¡Šç©©å®š>tertiary hemostasis or clot stabilization ä¸‰ç´šæ­¢è¡€æˆ–å‡å¡Šç©©å®š</a></li><li><a href=#fibrinolysis-çº–ç¶­è›‹ç™½æº¶è§£å‡å¡Šæº¶è§£>Fibrinolysis çº–ç¶­è›‹ç™½æº¶è§£ï¼ˆå‡å¡Šæº¶è§£ï¼‰</a><ol><li><a href=#errors-in-sample-collection>Errors in Sample Collection</a></li></ol></li></ol><ol><li><ol><li><a href=#pt--aptt-tt-fib-dd>ğŸ“PT ğŸ“ aPTTğŸ“ TTğŸ“ FIBğŸ“ DD</a></li></ol></li><li><a href=#prothrombin-time-pt-and-inr>Prothrombin Time (PT) and INR</a></li><li><a href=#causes-of-pt-prolongation>causes of PT prolongation</a><ol><li></li><li><a href=#1-pt-prolongtaion--underlying-conditions>1. PT prolongtaion : underlying conditions</a></li><li><a href=#2-pt-prolongtaion--anticoagulants>2. PT prolongtaion : anticoagulants</a></li></ol></li><li><a href=#limitations-of-pt>limitations of PT</a></li><li><a href=#activated-partial-thromboplastin-time-aptt>Activated Partial Thromboplastin Time (aPTT)</a></li><li><a href=#causes-of-aptt-prolongation>causes of aPTT prolongation</a><ol><li><a href=#anticoagulants-cause-aptt-prolognation>anticoagulants cause aPTT prolognation</a></li></ol></li><li><a href=#thrombin-time-tt>Thrombin Time (TT)</a></li><li><a href=#shourt-summary>Shourt Summary:</a><ol><li><a href=#screening-test-abnormalities-in-inherited-and-acquired-coagulopathies>Screening Test Abnormalities in Inherited and Acquired Coagulopathies</a></li></ol></li><li><a href=#fibrinogen-assay>Fibrinogen Assay</a><ol><li><a href=#fibrinogen-100-mgdl--cryoprecipitate>fibrinogen &lt;100 mg/dL : Cryoprecipitate</a></li></ol></li><li><a href=#d-dimer-test>D-dimer Test</a></li><li><a href=#cutoff-typically--500-mcgl-to-define-negative-d-dimer-assay>cutoff (typically &lt; 500 mcg/L) to define negative D-dimer assay</a></li><li><a href=#other-conditions-of-elevtaed-d-dimer>Other conditions of elevtaed D-Dimer</a></li><li><a href=#mixing-study>Mixing study:</a></li><li><a href=#coagulation-factor-levels>Coagulation factor levels:</a></li><li><a href=#dic-screen>DIC screen:</a></li></ol><ol><li><a href=#plt->Plt: â¬‡ï¸</a></li><li><a href=#pt-->PT: ğŸ†—</a></li><li><a href=#aptt->aPTT: ğŸ†—</a></li><li><a href=#tt->TT: ğŸ†—</a></li><li><a href=#fibrinogen->Fibrinogen: ğŸ†—</a></li></ol><ol><li><a href=#thrombocytopenia>Thrombocytopenia</a></li></ol><ol><li><a href=#plt--1>Plt: ğŸ†—</a></li><li><a href=#pt->PT: âŒ›âŒ›âŒ›âŒ›âŒ›</a></li><li><a href=#aptt--1>aPTT: ğŸ†—</a></li><li><a href=#tt--1>TT: ğŸ†—</a></li><li><a href=#fibrinogen--1>Fibrinogen: ğŸ†—</a></li></ol><ol><li><a href=#plt--2>Plt: ğŸ†—</a></li><li><a href=#pt---1>PT: ğŸ†—</a></li><li><a href=#aptt--2>aPTT: âŒ›âŒ›âŒ›âŒ›âŒ›</a></li><li><a href=#tt--2>TT: ğŸ†—</a></li><li><a href=#fibrinogen--2>Fibrinogen: ğŸ†—</a></li></ol><ol><li><a href=#plt--3>Plt: ğŸ†—</a></li><li><a href=#pt--1>PT: âŒ›âŒ›âŒ›âŒ›âŒ›</a></li><li><a href=#aptt--3>aPTT: âŒ›âŒ›âŒ›âŒ›âŒ›</a></li><li><a href=#tt--3>TT: ğŸ†—</a></li><li><a href=#fibrinogen--3>Fibrinogen: ğŸ†—</a></li></ol><ol><li><a href=#plt--4>Plt: ğŸ†—</a></li><li><a href=#pt--2>PT: ğŸ†—/âŒ›âŒ›âŒ›</a></li><li><a href=#aptt--4>aPTT: ğŸ†—/âŒ›âŒ›âŒ›</a></li><li><a href=#tt--4>TT: âŒ›âŒ›âŒ›âŒ›âŒ›</a></li><li><a href=#fibrinogen--4>Fibrinogen: â¬‡ï¸</a></li></ol><ol><li><a href=#plt--5>Plt: ğŸ†—</a></li><li><a href=#pt---2>PT: âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›</a></li><li><a href=#aptt--5>aPTT: âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›</a></li><li><a href=#tt--5>TT: âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›</a></li><li><a href=#fibrinogen--5>Fibrinogen: âŒ</a></li></ol><ol><li><a href=#plt--6>Plt: â¬‡ï¸</a></li><li><a href=#pt---3>PT: ğŸ†—/âŒ›âŒ›âŒ›</a></li><li><a href=#aptt--6>aPTT: ğŸ†—/âŒ›âŒ›âŒ›</a></li><li><a href=#tt--6>TT: ğŸ†—/âŒ›âŒ›âŒ›</a></li><li><a href=#fibrinogen--6>Fibrinogen: ğŸ†—/â¬‡ï¸</a></li></ol><ol><li><a href=#dic>DIC</a></li></ol><ol><li><a href=#plt--7>Plt: ğŸ†—</a></li><li><a href=#pt---4>PT: ğŸ†—</a></li><li><a href=#aptt--7>aPTT: ğŸ†—</a></li><li><a href=#tt--7>TT: ğŸ†—</a></li><li><a href=#fibrinogen--7>Fibrinogen: ğŸ†—</a></li></ol><ol><li><a href=#andexanet-alfa-factor-xa-decoy-receptor>Andexanet alfa (factor Xa decoy receptor)</a></li></ol></nav></details></aside><style scoped>h1{font-size:150px;font-weight:900}</style><a href=#coagultaion-testing><h1 id=coagultaion-testing><span class=hanchor arialabel=Anchor># </span>Coagultaion Testing</h1></a><hr><a href=#æ—å”éœ†><h3 id=æ—å”éœ†><span class=hanchor arialabel=Anchor># </span>æ—å”éœ†</h3></a><p>2023.05.31</p><hr><a href=#overview-of-hemostasis><h1 id=overview-of-hemostasis><span class=hanchor arialabel=Anchor># </span>Overview of Hemostasis</h1></a><a href=#primary-hemostasis--åˆç´šæ­¢è¡€><h3 id=primary-hemostasis--åˆç´šæ­¢è¡€><span class=hanchor arialabel=Anchor># </span>primary hemostasis åˆç´šæ­¢è¡€</h3></a><a href=#secondary-hemostasis-äºŒç´šæ­¢è¡€><h3 id=secondary-hemostasis-äºŒç´šæ­¢è¡€><span class=hanchor arialabel=Anchor># </span>secondary hemostasis äºŒç´šæ­¢è¡€</h3></a><hr><a href=#primary-hemostasis--åˆç´šæ­¢è¡€-1><h2 id=primary-hemostasis--åˆç´šæ­¢è¡€-1><span class=hanchor arialabel=Anchor># </span>primary hemostasis åˆç´šæ­¢è¡€</h2></a><ul><li>è¡€å°æ¿çš„æ­£å¸¸åŠŸèƒ½ : ğŸ‘®ç›£æ¸¬è¡€ç®¡å…§çš®çš„å®Œæ•´æ€§ä¸¦åœ¨è¡€ç®¡æå‚·éƒ¨ä½å½¢æˆæ “å¡ä»¥é˜»æ­¢å’Œé˜²æ­¢è¡€æ¶²æ»²æ¼åˆ°è¡€ç®¡å¤–</li><li>æ²’æœ‰è¡€ç®¡æå‚· : å‰åˆ—ç’°ç´ ï¼ˆprostaglandinï¼‰å’Œå…§çš®ç´°èƒåˆ†æ³Œçš„ä¸€æ°§åŒ–æ°®çš„æŠ‘åˆ¶ğŸ”</li><li>è¡€ç®¡æå‚·å’Œå…§çš®æå‚·<ul><li>äº¤æ„Ÿç¥ç¶“ç³»çµ±è¢«å•Ÿå‹•ä¸¦å¼•èµ·è¡€ç®¡æ”¶ç¸®</li><li>collagen, fibronectin, and laminin : exposed to circulating blood</li><li>ğŸ‘·è¡€å°æ¿é™„åœ¨æš´éœ²çš„å…§çš®ä¸‹åŸºè³ªè›‹ç™½ä¸Šï¼Œé–‹å§‹æ­¢è¡€æ “å½¢æˆéç¨‹</li></ul></li></ul><hr><a href=#secretion-of-storage-granule-content><h3 id=secretion-of-storage-granule-content><span class=hanchor arialabel=Anchor># </span>secretion of storage granule content</h3></a><ul><li>è¡€å°æ¿é¡†ç²’ : å«æœ‰æ•¸åƒç¨®è›‹ç™½è³ªï¼Œå•Ÿå‹•å¾Œé‡‹æ”¾</li><li><code>3 major secretory granules</code><ul><li>alpha-granules<ul><li>å‡è¡€å› å­ï¼ˆIã€IIã€V å’Œ XIï¼‰ã€</li><li>fibrinolysis system components</li><li>coagulation inhibitors</li><li>complement components (C1 inhibitor, C3, and C4)</li></ul></li><li>delta-granules<ul><li>ADP</li></ul></li><li>lysosomes</li></ul></li></ul><hr><a href=#during-platelet-activation-è¡€å°æ¿æ´»åŒ–><h3 id=during-platelet-activation-è¡€å°æ¿æ´»åŒ–><span class=hanchor arialabel=Anchor># </span>during platelet activation è¡€å°æ¿æ´»åŒ–</h3></a><ul><li>ï¼ˆADPã€thromboxane A2ï¼‰å•Ÿå‹•ä¿¡è™Ÿé€šè·¯ï¼Œå°‡ GPIIb/IIIa è½‰åŒ–ç‚º divalent fibrinogen</li><li>fibrinogen ğŸ‘‰ èšé›†/å‡èš</li></ul><a href=#platelet-aggregation--è¡€å°æ¿èšé›†><h3 id=platelet-aggregation--è¡€å°æ¿èšé›†><span class=hanchor arialabel=Anchor># </span>platelet aggregation è¡€å°æ¿èšé›†</h3></a><ul><li>GPIIb/IIIa<ul><li>å‹Ÿé›†é¡å¤–çš„è¡€å°æ¿</li></ul></li><li>transmembrane ADP receptors P2Y1 and P2Y12<ul><li>è¡€å°æ¿å½¢æ…‹å­¸è®ŠåŒ–</li><li>è¡€å°æ¿èšé›†</li></ul></li></ul><hr><a href=#secondary-hemostasis-äºŒç´šæ­¢è¡€-1><h2 id=secondary-hemostasis-äºŒç´šæ­¢è¡€-1><span class=hanchor arialabel=Anchor># </span>secondary hemostasis äºŒç´šæ­¢è¡€</h2></a><ul><li>æ²’æµè¡€æ™‚ï¼š<ul><li>inactive precursor enzymes (zymogens)</li><li>åœ¨è¡€æ¼¿ä¸­å¾ªç’°</li></ul></li><li>æµè¡€æ™‚ï¼š<ul><li>å°è‡´fibrin polymerizationå’Œè¡€å°æ¿æ´»åŒ–ï¼Œ</li><li>å½¢æˆclot</li></ul></li><li>2 å€‹é€”å¾‘ :<ul><li>extrinsic</li><li>intrinsic</li></ul></li></ul><hr><p><img src=https://i.imgur.com/A4GWEtH.png width=auto alt=" h:650"></p><hr><a href=#coagulation-factor---i><h2 id=coagulation-factor---i><span class=hanchor arialabel=Anchor># </span>Coagulation Factor - I</h2></a><ol><li>I - fibrinogen</li><li>II - prothrombin</li></ol><hr><ol start=3><li>III - tissue thromboplastin (tissue factor)</li></ol><hr><ol start=4><li>IV - ionized calcium ( Ca++ )</li><li>V - labile factor or proaccelerin</li></ol><ul><li>PL : platelet membrane phospholipid</li></ul><hr><ol start=7><li>VII - stable factor or proconvertin</li></ol><hr><a href=#coagulation-factor---ii><h2 id=coagulation-factor---ii><span class=hanchor arialabel=Anchor># </span>Coagulation Factor - II</h2></a><ol start=8><li>VIII - antihemophilic factor</li><li>IX - plasma thromboplastin component, Christmas factor</li><li><code>X - Stuart-Prower factor</code></li><li>XI - plasma thromboplastin antecedent</li><li>XII - Hageman factor</li></ol><hr><ol start=13><li>XIII - fibrin-stabilizing factor</li></ol><hr><a href=#extrinsic-pathway><h2 id=extrinsic-pathway><span class=hanchor arialabel=Anchor># </span>Extrinsic pathway</h2></a><ul><li>è¡€ç®¡æå‚·æˆ–å–®æ ¸ç´°èƒå•Ÿå‹•å°è‡´ VIIï¼ˆVIIaï¼‰å•Ÿå‹•</li><li>å•Ÿå‹• IX (intrinsicï¼‰å’Œ Xï¼ˆcommonï¼‰</li></ul><a href=#intrinsic-pathway><h2 id=intrinsic-pathway><span class=hanchor arialabel=Anchor># </span>Intrinsic pathway</h2></a><ul><li>ç”± XII è½‰åŒ–ç‚º XIIa é–‹å§‹</li><li>XI å’Œ IX é€æ­¥è½‰åŒ–ç‚ºå…¶æ´»æ€§å½¢å¼</li><li>VIIIa ï¼ˆç”±thrombinå•Ÿå‹•ï¼‰<ul><li>åœ¨æ´»åŒ–çš„è¡€å°æ¿è¡¨é¢ä½œç‚º IXa çš„Cofactor</li><li>ä¿ƒé€² X to Xa</li></ul></li></ul><hr><a href=#ç„¶å¾Œå…©æ¢è·¯å¾‘åŒ¯èšåˆ°common-pathwyaå…±åŒè·¯å¾‘><h2 id=ç„¶å¾Œå…©æ¢è·¯å¾‘åŒ¯èšåˆ°common-pathwyaå…±åŒè·¯å¾‘><span class=hanchor arialabel=Anchor># </span>ç„¶å¾Œå…©æ¢è·¯å¾‘åŒ¯èšåˆ°Common Pathwyaå…±åŒè·¯å¾‘</h2></a><ul><li>Xå•Ÿå‹•ç‚ºXa</li><li>Xa å°‡prothrombinè½‰åŒ–ç‚ºthrombinï¼Œcofactor Va å¯åŠ é€Ÿåæ‡‰</li><li>thrombinå°‡fibrinogenè½‰åŒ–ç‚ºfibrin</li><li>fibrin clot å½¢æˆ</li></ul><hr><a href=#tertiary-hemostasis-or-clot-stabilization-ä¸‰ç´šæ­¢è¡€æˆ–å‡å¡Šç©©å®š><h2 id=tertiary-hemostasis-or-clot-stabilization-ä¸‰ç´šæ­¢è¡€æˆ–å‡å¡Šç©©å®š><span class=hanchor arialabel=Anchor># </span>tertiary hemostasis or clot stabilization ä¸‰ç´šæ­¢è¡€æˆ–å‡å¡Šç©©å®š</h2></a><ul><li>thrombinçš„å°‡ XIII å•Ÿå‹•ç‚º XIIIa</li><li>XIIIa <code>cross-links</code> stabilizing fibrin</li></ul><hr><a href=#fibrinolysis-çº–ç¶­è›‹ç™½æº¶è§£å‡å¡Šæº¶è§£><h2 id=fibrinolysis-çº–ç¶­è›‹ç™½æº¶è§£å‡å¡Šæº¶è§£><span class=hanchor arialabel=Anchor># </span>Fibrinolysis çº–ç¶­è›‹ç™½æº¶è§£ï¼ˆå‡å¡Šæº¶è§£ï¼‰</h2></a><ul><li>tissue-type plasminogen (tPA) æˆ– uPA :<ul><li>plasminogen to plasmin</li></ul></li><li>plasminåˆ‡å‰²fibriné‡‹æ”¾fibrin degradation products(FDP) and D-dimer</li><li>fibrinolysisé€Ÿç‡å–æ±ºæ–¼ tPA æ¿ƒåº¦ï¼Œè©²æ¿ƒåº¦ç”±ä»¥ä¸‹å› ç´ æ§åˆ¶:<ul><li>å…§çš®åˆ†æ³Œ tPA çš„é€Ÿç‡</li><li>è‚è‡Ÿæ¸…é™¤ tPA çš„é€Ÿç‡</li><li>tPA inhibitorã€PAI-1çš„æ¿ƒåº¦</li></ul></li><li>ç ´å£ tPA çš„åˆ†æ³Œã€æŠ‘åˆ¶å’Œæ¸…é™¤ä¹‹é–“çš„å¹³è¡¡å¯å°è‡´ :<ul><li>å‡ºè¡€ï¼ˆfibrinolysisäº¢é€²ï¼‰</li><li>è¡€æ “å½¢æˆï¼ˆfibrinolysisæ¸›é€€ï¼‰</li></ul></li></ul><hr><a href=#errors-in-sample-collection><h3 id=errors-in-sample-collection><span class=hanchor arialabel=Anchor># </span>Errors in Sample Collection</h3></a><p><img src=https://i.imgur.com/VAACBhR.png width=auto alt=" h:550"></p><hr><a href=#åŸºæœ¬å‡è¡€äº”é …><h1 id=åŸºæœ¬å‡è¡€äº”é …><span class=hanchor arialabel=Anchor># </span>åŸºæœ¬å‡è¡€äº”é …</h1></a><hr><a href=#pt--aptt-tt-fib-dd><h3 id=pt--aptt-tt-fib-dd><span class=hanchor arialabel=Anchor># </span>ğŸ“PT ğŸ“ aPTTğŸ“ TTğŸ“ FIBğŸ“ DD</h3></a><hr><ol><li>Prothrombin Time (PT) and INR</li><li>Activated Partial Thromboplastin Time (aPTT)</li><li>Thrombin Time (TT)</li><li>Clauss Fibrinogen Assay</li><li>D-dimer Test</li></ol><hr><a href=#prothrombin-time-pt-and-inr><h2 id=prothrombin-time-pt-and-inr><span class=hanchor arialabel=Anchor># </span>Prothrombin Time (PT) and INR</h2></a><hr><ul><li>VIIï¼ˆå¤–æºæ€§é€”å¾‘ï¼‰ã€å› å­ IIã€V å’Œ Xï¼Œä»¥åŠfibrinogenï¼ˆå…±åŒé€”å¾‘ï¼‰</li><li>PT çš„åƒè€ƒç¯„åœå› è©¦åŠ‘å’Œå„€å™¨è€Œç•°ï¼›é€šå¸¸åœ¨ 10 ç§’åˆ° 13 ç§’ä¹‹é–“</li><li>INR = (patient&rsquo;s PT/ Control PT)<sup>ISI</sup></li></ul><a href=#causes-of-pt-prolongation><h2 id=causes-of-pt-prolongation><span class=hanchor arialabel=Anchor># </span>causes of PT prolongation</h2></a><ol><li>underlying conditions</li><li>anticoagulants</li><li>acute dilutional coagulopathy</li></ol><a href=#shortened-pt-may-suggest-a-hypercoagulable-state-but-it-is-not-used-to-guide-patient-care-in-practice><h6 id=shortened-pt-may-suggest-a-hypercoagulable-state-but-it-is-not-used-to-guide-patient-care-in-practice><span class=hanchor arialabel=Anchor># </span>Shortened PT may suggest a hypercoagulable state, but it is not used to guide patient care in practice.</h6></a><hr><a href=#1-pt-prolongtaion--underlying-conditions><h3 id=1-pt-prolongtaion--underlying-conditions><span class=hanchor arialabel=Anchor># </span>1. PT prolongtaion : underlying conditions</h3></a><ul><li>factor VII (extrinsic pathway)</li><li>factors V, VII, and/or X, prothrombin, and/or fibrinogen (common pathway)</li><li><code>vitamin K deficiency</code></li><li>liver disease</li><li>afibrinogenemia, hypofibrinogenemia, or dysfibrinogenemia
disseminated intravascular coagulation</li><li>elevated fibrin degradation products</li><li>some lupus anticoagulant (uncommon)/antiphospholipid antibodies</li></ul><hr><a href=#2-pt-prolongtaion--anticoagulants><h3 id=2-pt-prolongtaion--anticoagulants><span class=hanchor arialabel=Anchor># </span>2. PT prolongtaion : anticoagulants</h3></a><ul><li>vitamin K antagonists including <code>warfarin</code></li><li>factor Xa inhibitors including <code>rivaroxaban</code> and to a lesser extent, apixaban</li><li><code>unfractionated heparin</code> (generally at high doses; PT/INR not typically affected by low-molecular-weight heparin)</li><li>parenteral or oral direct thrombin inhibitors such as bivalirudin or dabigatran</li></ul><hr><a href=#limitations-of-pt><h2 id=limitations-of-pt><span class=hanchor arialabel=Anchor># </span>limitations of PT</h2></a><ul><li>inability to detect most <code>fibrinogen disorders</code></li><li>there are variations among PT assay reagents with different sensitivities to factor deficiencies, thus<ul><li>normal PT <code>does not rule out factor deficiencies</code></li><li>prolonged PT <code>does not necessarily reflect bleeding risk</code></li></ul></li></ul><hr><a href=#activated-partial-thromboplastin-time-aptt><h2 id=activated-partial-thromboplastin-time-aptt><span class=hanchor arialabel=Anchor># </span>Activated Partial Thromboplastin Time (aPTT)</h2></a><ul><li>factors XII, XI, IX, VIII (intrinsic pathway)</li><li>factors II, V, and X, and fibrinogen (common pathway)</li></ul><hr><ul><li>screening : bleeding disorders due to deficiencies of, or inhibitors to coagulation factors</li><li>monitoring : unfractionated heparin therapy</li><li>assessment : disseminated intravascular coagulation</li><li>monitoring : liver disease status</li><li>screening : lupus anticoagulant</li></ul><hr><a href=#causes-of-aptt-prolongation><h2 id=causes-of-aptt-prolongation><span class=hanchor arialabel=Anchor># </span>causes of aPTT prolongation</h2></a><ul><li><code>factor XII deficiency</code> : most common</li><li>acquired or inherited deficiencies or inhibition<ul><li>factors XI, IX (<code>hemophilia B</code>),</li><li>factors VIII (including <code>hemophilia A</code>), X, II, and fibrinogen (though aPTT does not detect most fibrinogen disorders)</li></ul></li><li><code>vitamin K deficiency</code></li><li>presence of <code>lupus anticoagulant</code></li><li>severe <code>von Willebrand disease</code></li><li>disseminated intravascular coagulation (DIC)</li><li>liver disease</li></ul><hr><a href=#anticoagulants-cause-aptt-prolognation><h3 id=anticoagulants-cause-aptt-prolognation><span class=hanchor arialabel=Anchor># </span>anticoagulants cause aPTT prolognation</h3></a><ul><li>high doses of vitamin K antagonists, <strong>although prothrombin time</strong> is more sensitive for vitamin K antagonist</li><li>heparin (particularly unfractionated heparin)</li><li>bivalirudin or dabigatran</li><li>factor Xa inhibitors such as apixaban and rivaroxaban</li></ul><hr><a href=#thrombin-time-tt><h2 id=thrombin-time-tt><span class=hanchor arialabel=Anchor># </span>Thrombin Time (TT)</h2></a><ul><li>detection of <code>hypofibrinogenemia and dysfibrinogenemia</code></li><li>detection of <code>thrombin inhibitors</code></li><li>other testing usually provide sufficient information without the use of TT in patients requiring investigation of inherited disorders of secondary hemostasis</li></ul><hr><a href=#shourt-summary><h2 id=shourt-summary><span class=hanchor arialabel=Anchor># </span>Shourt Summary:</h2></a><hr><a href=#screening-test-abnormalities-in-inherited-and-acquired-coagulopathies><h3 id=screening-test-abnormalities-in-inherited-and-acquired-coagulopathies><span class=hanchor arialabel=Anchor># </span>Screening Test Abnormalities in Inherited and Acquired Coagulopathies</h3></a><p><img src=https://i.imgur.com/Pl2E669.png width=auto alt=h:200></p><hr><a href=#fibrinogen-assay><h2 id=fibrinogen-assay><span class=hanchor arialabel=Anchor># </span>Fibrinogen Assay</h2></a><p>normal fibrinogen concentration ranges from 200 mg/dL (2 g/L) to 400 mg/dL (4 g/L)</p><hr><ul><li>afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia</li><li>liver disease</li><li>disseminated intravascular coagulation (DIC)</li><li>primary fibrinolysis</li></ul><a href=#fibrinogen-100-mgdl--cryoprecipitate><h3 id=fibrinogen-100-mgdl--cryoprecipitate><span class=hanchor arialabel=Anchor># </span>fibrinogen &lt;100 mg/dL : Cryoprecipitate</h3></a><ul><li>1 unit of cryo per 5kg patient weight will increase fibrinogen by about 100 mg/dL</li></ul><hr><a href=#d-dimer-test><h2 id=d-dimer-test><span class=hanchor arialabel=Anchor># </span>D-dimer Test</h2></a><ul><li>exclusion of venous thromboembolism (VTE) in patients with low clinical probability by clinical prediction scores</li><li>prediction of risk of recurrent VTE, thus aiding in decision making regarding duration of anticoagulation therapy in patients with VTE</li><li>diagnosis and management of <strong>disseminated intravascular coagulation</strong></li><li>exclusion of <strong>acute aortic dissection</strong></li><li>monitoring for thrombotic complications in patients with severe infections and sepsis</li></ul><hr><p><img src=https://i.imgur.com/4XKXKgG.png width=auto alt=" h:600"></p><blockquote><p>Freund Y, Cohen-Aubart F, Bloom B. Acute Pulmonary Embolism: A Review. JAMA. 2022;328(13):1336-1345. doi:10.1001/jama.2022.16815</p></blockquote><hr><a href=#cutoff-typically--500-mcgl-to-define-negative-d-dimer-assay><h2 id=cutoff-typically--500-mcgl-to-define-negative-d-dimer-assay><span class=hanchor arialabel=Anchor># </span>cutoff (typically &lt; 500 mcg/L) to define negative D-dimer assay</h2></a><ul><li>higher threshold (&lt; 1,000 mcg/L) in patients with low clinical pretest probability</li><li>cutoff of &lt; 500 mcg/L may be used in patients with moderate pretest probability</li></ul><hr><a href=#other-conditions-of-elevtaed-d-dimer><h2 id=other-conditions-of-elevtaed-d-dimer><span class=hanchor arialabel=Anchor># </span>Other conditions of elevtaed D-Dimer</h2></a><ul><li>being an inpatient</li><li>advanced age</li><li>cancer</li><li>disseminated intravascular coagulation (DIC)</li><li>infection</li><li>inflammatory conditions</li><li>recent surgery or trauma</li><li>liver disease, renal disease</li><li>atrial fibrillation</li><li>stroke</li><li>thrombolytic therapy</li></ul><hr><a href=#mixing-study><h2 id=mixing-study><span class=hanchor arialabel=Anchor># </span>Mixing study:</h2></a><ul><li>useful if â¬†ï¸ PT or PTT</li><li>mix Ptâ€™s plasma 1:1 with normal plasma</li><li>and retest<ul><li>PT/PTT normalizes<ul><li>ğŸ‘‰ factor deficiency</li></ul></li><li>PT/PTT remains elevated<ul><li>ğŸ‘‰ factor inhibitor</li></ul></li></ul></li></ul><hr><a href=#coagulation-factor-levels><h2 id=coagulation-factor-levels><span class=hanchor arialabel=Anchor># </span>Coagulation factor levels:</h2></a><ul><li>useful if mixing study suggests factor deficiency</li><li>DIC â†’ all factors consumed
âˆ´ â†“ factors V and VIII</li><li>Liver disease
â†’ â†“ all factors except VIII
âˆ´ â†“ factor V, normal factor VIII</li><li>Vitamin K deficiency
â†’ â†“ factors II, VII, IX, X (and protein C, S);
âˆ´ normal V and VIII</li></ul><hr><p>VIII: by vascular, glomerular, and tubular endothelium, and the sinusoidal cells of the liver</p><hr><a href=#dic-screen><h2 id=dic-screen><span class=hanchor arialabel=Anchor># </span>DIC screen:</h2></a><ul><li>â†“ fibrinogen
(consumed)</li><li>fibrin degradation products
(FDPs, âŠ• from intense fibrinolysis),</li><li>â†‘ D-dimer
(more specific FDP test that detects degradation of X-linked fibrin)</li></ul><hr><a href=#question-1><h1 id=question-1><span class=hanchor arialabel=Anchor># </span>Question 1:</h1></a><hr><br><a href=#plt-><h2 id=plt-><span class=hanchor arialabel=Anchor># </span>Plt: â¬‡ï¸</h2></a><a href=#pt--><h2 id=pt--><span class=hanchor arialabel=Anchor># </span>PT: ğŸ†—</h2></a><a href=#aptt-><h2 id=aptt-><span class=hanchor arialabel=Anchor># </span>aPTT: ğŸ†—</h2></a><a href=#tt-><h2 id=tt-><span class=hanchor arialabel=Anchor># </span>TT: ğŸ†—</h2></a><a href=#fibrinogen-><h2 id=fibrinogen-><span class=hanchor arialabel=Anchor># </span>Fibrinogen: ğŸ†—</h2></a><hr><a href=#answer><h1 id=answer><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><a href=#thrombocytopenia><h2 id=thrombocytopenia><span class=hanchor arialabel=Anchor># </span>Thrombocytopenia</h2></a><hr><a href=#question-2><h1 id=question-2><span class=hanchor arialabel=Anchor># </span>Question 2:</h1></a><hr><br><a href=#plt--1><h2 id=plt--1><span class=hanchor arialabel=Anchor># </span>Plt: ğŸ†—</h2></a><a href=#pt-><h2 id=pt-><span class=hanchor arialabel=Anchor># </span>PT: âŒ›âŒ›âŒ›âŒ›âŒ›</h2></a><a href=#aptt--1><h2 id=aptt--1><span class=hanchor arialabel=Anchor># </span>aPTT: ğŸ†—</h2></a><a href=#tt--1><h2 id=tt--1><span class=hanchor arialabel=Anchor># </span>TT: ğŸ†—</h2></a><a href=#fibrinogen--1><h2 id=fibrinogen--1><span class=hanchor arialabel=Anchor># </span>Fibrinogen: ğŸ†—</h2></a><hr><a href=#answer-1><h1 id=answer-1><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Factor VII deficiency or inhibitor</li><li>early vitamin K deficiency</li></ul><hr><a href=#question-3><h1 id=question-3><span class=hanchor arialabel=Anchor># </span>Question 3:</h1></a><hr><br><a href=#plt--2><h2 id=plt--2><span class=hanchor arialabel=Anchor># </span>Plt: ğŸ†—</h2></a><a href=#pt---1><h2 id=pt---1><span class=hanchor arialabel=Anchor># </span>PT: ğŸ†—</h2></a><a href=#aptt--2><h2 id=aptt--2><span class=hanchor arialabel=Anchor># </span>aPTT: âŒ›âŒ›âŒ›âŒ›âŒ›</h2></a><a href=#tt--2><h2 id=tt--2><span class=hanchor arialabel=Anchor># </span>TT: ğŸ†—</h2></a><a href=#fibrinogen--2><h2 id=fibrinogen--2><span class=hanchor arialabel=Anchor># </span>Fibrinogen: ğŸ†—</h2></a><hr><a href=#answer-2><h1 id=answer-2><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Factor VIII, IX, or XI deficiency or inhibitor</li><li>Factor XII, prekallikrein, high-molecular-weight kininogen deficiency</li><li>vWD</li><li>Lupus Anticoagulant</li></ul><hr><a href=#question-4><h1 id=question-4><span class=hanchor arialabel=Anchor># </span>Question 4:</h1></a><hr><br><a href=#plt--3><h2 id=plt--3><span class=hanchor arialabel=Anchor># </span>Plt: ğŸ†—</h2></a><a href=#pt--1><h2 id=pt--1><span class=hanchor arialabel=Anchor># </span>PT: âŒ›âŒ›âŒ›âŒ›âŒ›</h2></a><a href=#aptt--3><h2 id=aptt--3><span class=hanchor arialabel=Anchor># </span>aPTT: âŒ›âŒ›âŒ›âŒ›âŒ›</h2></a><a href=#tt--3><h2 id=tt--3><span class=hanchor arialabel=Anchor># </span>TT: ğŸ†—</h2></a><a href=#fibrinogen--3><h2 id=fibrinogen--3><span class=hanchor arialabel=Anchor># </span>Fibrinogen: ğŸ†—</h2></a><hr><a href=#answer-3><h1 id=answer-3><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Prothrombin, factor V, or factor X deficiency or inhibitor</li><li>Deficiency or inhibitor against factors in both intrinsic and extrinsic pathway,<ul><li>for example,<ul><li>liver disease</li><li>DIC,</li><li>vitamin K deficiency</li></ul></li></ul></li><li>Factor V Short</li></ul><hr><a href=#question-5><h1 id=question-5><span class=hanchor arialabel=Anchor># </span>Question 5:</h1></a><hr><br><a href=#plt--4><h2 id=plt--4><span class=hanchor arialabel=Anchor># </span>Plt: ğŸ†—</h2></a><a href=#pt--2><h2 id=pt--2><span class=hanchor arialabel=Anchor># </span>PT: ğŸ†—/âŒ›âŒ›âŒ›</h2></a><a href=#aptt--4><h2 id=aptt--4><span class=hanchor arialabel=Anchor># </span>aPTT: ğŸ†—/âŒ›âŒ›âŒ›</h2></a><a href=#tt--4><h2 id=tt--4><span class=hanchor arialabel=Anchor># </span>TT: âŒ›âŒ›âŒ›âŒ›âŒ›</h2></a><a href=#fibrinogen--4><h2 id=fibrinogen--4><span class=hanchor arialabel=Anchor># </span>Fibrinogen: â¬‡ï¸</h2></a><hr><a href=#answer-4><h1 id=answer-4><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Hypofibrinogenemia</li><li>Dysfibrinogenemia</li></ul><hr><a href=#question-6><h1 id=question-6><span class=hanchor arialabel=Anchor># </span>Question 6:</h1></a><hr><br><a href=#plt--5><h2 id=plt--5><span class=hanchor arialabel=Anchor># </span>Plt: ğŸ†—</h2></a><a href=#pt---2><h2 id=pt---2><span class=hanchor arialabel=Anchor># </span>PT: âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›</h2></a><a href=#aptt--5><h2 id=aptt--5><span class=hanchor arialabel=Anchor># </span>aPTT: âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›</h2></a><a href=#tt--5><h2 id=tt--5><span class=hanchor arialabel=Anchor># </span>TT: âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›âŒ›</h2></a><a href=#fibrinogen--5><h2 id=fibrinogen--5><span class=hanchor arialabel=Anchor># </span>Fibrinogen: âŒ</h2></a><hr><a href=#answer-5><h1 id=answer-5><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Afibrinogenemia</li></ul><hr><a href=#question-7><h1 id=question-7><span class=hanchor arialabel=Anchor># </span>Question 7:</h1></a><hr><br><a href=#plt--6><h2 id=plt--6><span class=hanchor arialabel=Anchor># </span>Plt: â¬‡ï¸</h2></a><a href=#pt---3><h2 id=pt---3><span class=hanchor arialabel=Anchor># </span>PT: ğŸ†—/âŒ›âŒ›âŒ›</h2></a><a href=#aptt--6><h2 id=aptt--6><span class=hanchor arialabel=Anchor># </span>aPTT: ğŸ†—/âŒ›âŒ›âŒ›</h2></a><a href=#tt--6><h2 id=tt--6><span class=hanchor arialabel=Anchor># </span>TT: ğŸ†—/âŒ›âŒ›âŒ›</h2></a><a href=#fibrinogen--6><h2 id=fibrinogen--6><span class=hanchor arialabel=Anchor># </span>Fibrinogen: ğŸ†—/â¬‡ï¸</h2></a><hr><a href=#answer-6><h1 id=answer-6><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><a href=#dic><h2 id=dic><span class=hanchor arialabel=Anchor># </span>DIC</h2></a><hr><a href=#question-8><h1 id=question-8><span class=hanchor arialabel=Anchor># </span>Question 8:</h1></a><hr><br><a href=#plt--7><h2 id=plt--7><span class=hanchor arialabel=Anchor># </span>Plt: ğŸ†—</h2></a><a href=#pt---4><h2 id=pt---4><span class=hanchor arialabel=Anchor># </span>PT: ğŸ†—</h2></a><a href=#aptt--7><h2 id=aptt--7><span class=hanchor arialabel=Anchor># </span>aPTT: ğŸ†—</h2></a><a href=#tt--7><h2 id=tt--7><span class=hanchor arialabel=Anchor># </span>TT: ğŸ†—</h2></a><a href=#fibrinogen--7><h2 id=fibrinogen--7><span class=hanchor arialabel=Anchor># </span>Fibrinogen: ğŸ†—</h2></a><hr><a href=#answer-7><h1 id=answer-7><span class=hanchor arialabel=Anchor># </span>Answer</h1></a><hr><ul><li>Factor <code>XIII deficiency</code> or inhibitor</li><li>Fibrinolytic defects</li><li><code>vWD</code> (only affecting collagen binding function, though aPTT is often elevated)</li><li>Disorder of <code>blood vessel wall</code></li><li>Combination of mild deficiency of coagulation factors, VWF, and undetected IPFD</li><li><code>Platelet function defects</code> e.g. CKD</li></ul><hr><a href=#clotting-cascade-and-anticoagulants><h1 id=clotting-cascade-and-anticoagulants><span class=hanchor arialabel=Anchor># </span>Clotting cascade and anticoagulants</h1></a><hr><p><img src=https://i.imgur.com/RG3EW7j.png width=auto alt=h:550></p><hr><p>Properties and Antidotes for Anticoagulants & Fibrinolytics</p><table><thead><tr><th>Anticoag.</th><th>t1/2</th><th>Labs</th><th>Rx for O/D w/ Serious Bleeding (+ d/c anticoag)</th></tr></thead><tbody><tr><td>UFH</td><td>60â€“90â€²</td><td>â†‘ PTT</td><td>Protamine IV 1 mg/100 U UFH (max 50 mg). For infusions, dose to reverse 2Ã— UFH given per h.</td></tr><tr><td>LMWH</td><td>2â€“7Â°</td><td>anti-Xa*</td><td>Protamine reverses ~60%. 1 mg per 1 mg enox.</td></tr><tr><td>Bivalirudin</td><td>25â€²</td><td>â†‘ PTT</td><td>Dialysis</td></tr><tr><td>Argatroban</td><td>45â€²</td><td>â†‘ PTT</td><td>? Dialysis</td></tr><tr><td>Warfarin</td><td>36Â°</td><td>â†‘ PT</td><td><code>No bleeding</code>: vit K 2.5 mg PO if INR >9, o/w no e/o clinical benefit (Blood Adv 2019;3:789)</td></tr><tr><td></td><td></td><td></td><td><code>Bleeding</code>: vit. K 10 mg IV + either 4F-PCC (KCentra, 25, 35, or 50 U/kg for INR 2â€“4, 4â€“6, or >6) or FFP 2â€“4 U IV q6â€“8h (slower, more volume)</td></tr></tbody></table><hr><p>Properties and Antidotes for Anticoagulants & Fibrinolytics</p><table><thead><tr><th>Fibrinolytic</th><th>t1/2</th><th>Labs</th><th>Rx for O/D w/ Serious Bleeding (+ d/c anticoag)</th></tr></thead><tbody><tr><td>Fibrinolytic</td><td>20â€², LK</td><td>â†“ fbgn</td><td>Cryo, FFP, Â± tranexamic or aminocaproic acid</td></tr><tr><td>Rivaroxaban<br>Apixaban<br>Dabigatran</td><td>8â€“12Â°<br>K > L</td><td>â†‘ PT*<br>anti-Xa*</td><td><code>Andexanet alfa</code></td></tr><tr><td>Dabigatran</td><td>~12Â°</td><td>K</td><td>â†‘ PTT* Idarucizumab: mAb binds drug (NEJM 2017;377:431)</td></tr></tbody></table><pre><code>* Mode of excretion: 
    * K, kidney
    * L, liver 
    * RES, reticuloendothelial system
</code></pre><hr><a href=#andexanet-alfa-factor-xa-decoy-receptor><h2 id=andexanet-alfa-factor-xa-decoy-receptor><span class=hanchor arialabel=Anchor># </span>Andexanet alfa (factor Xa decoy receptor)</h2></a><p>reverse apixaban and rivaroxaban in patients with life-threatening or uncontrolled bleeding</p><ul><li>800 mg bolus (30 mg/min)</li><li>â†’ 8 mg/min infusion<ul><li>(Â½ of above if taking Â½ dose DOAC or â‰¥8 hrs since last dose; NEJM 2019;380:1326);</li></ul></li><li>4F-PCC: prothrombin complex concentrate (FII, VII, IX, X; Protein C & S). if andexanet not available</li></ul><hr><p><img src=https://i.imgur.com/vjuYH8L.png width=auto alt=h:650></p><blockquote><p>Activated Protein C (APC)</p></blockquote><hr><a href=#the-end><h1 id=the-end><span class=hanchor arialabel=Anchor># </span>THE END</h1></a></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li>ğŸ¤­æ²’æœ‰æ‰¾åˆ°åå‘é€£çµ</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>